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Summary
Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. 
Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here 
we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH.
Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, 
non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least one 
accompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to 
receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other 
chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpoints 
for the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH 
resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. 
Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose 
of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. 
The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is 
ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6.
Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at 
least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in 
the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis 
improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg 
group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was 
not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in 
the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the 
most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg 
group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The 
overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar 
across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 
93 [14%] in the obeticholic acid 25 mg group).
Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity 
among patients with NASH. The results from this planned interim analysis show clinically significant histological 
improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes.
Funding Intercept Pharmaceuticals.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Non-alcoholic steatohepatitis (NASH) is an increasingly 
common cause of chronic liver disease, characterised by 
hepatocellular injury, inflammation, and progressive 
fibrosis. Models of disease progression project that the 
overall burden of end-stage liver disease due to NASH 
is likely to increase two to three times over the next 
two decades.1 Currently, there are no approved therapies 
for NASH.
The farnesoid X receptor is a nuclear receptor that 
plays a central role in the regulation of bile acids and 
metabolism.2 Recent data indicate that activation of the 
farnesoid X receptor can also reduce hepatic fibrosis 
and inflammation.2–5 Previous placebo-controlled clinical 
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studies have shown that obeticholic acid, a potent and 
selective farnesoid X receptor agonist, improves glucose 
disposal after short-term administration6 and key histo-
logical features of NASH, including fibrosis.7 Based on a 
previous phase 3 study, obeticholic acid was approved for 
the treatment of primary biliary cholangitis, a progressive 
autoimmune liver disease, in patients with an inadequate 
response to, or unable to tolerate, ursodeoxycholic acid.8 
Collectively, this provided a strong rationale for assessing 
the efficacy and safety of obeticholic acid in patients with 
NASH and fibrosis in this pivotal phase 3 study.
Liver-related outcomes in patients with NASH 
principally occur after the development of cirrhosis; 
halting progression to cirrhosis is therefore a key 
treatment goal. Given the length of time to progress to 
cirrhosis and clinical outcomes, a conditional approval 
pathway based on demonstration of histological improve-
ment following at least 12 months of treatment is 
supported by the US Food and Drug Administration 
(FDA) and the European Medicines Agency.9,10
The Randomised Global Phase 3 Study to Evaluate the 
Impact on NASH with Fibrosis of Obeticholic Acid 
Treatment (REGENERATE) study is a randomised, 
controlled, phase 3 study of obeticholic acid in patients 
with NASH and fibrosis.11 Here, we report the results of 
the prespecified month 18 interim analysis on the safety 
and efficacy of obeticholic acid in improving fibrosis and 
underlying disease activity.
Methods
Study design and participants
This multicentre, randomised, double-blind, placebo-
controlled, phase 3 study is being conducted at 
332 centres in 20 countries across the world. Eligible 
patients were adults (aged ≥18 years) with histological 
evidence of (per central expert pathologist reading of a 
liver biopsy obtained ≤6 months from randomisation) 
definite steatohepatitis; a non-alcoholic fatty liver disease 
(NAFLD) activity score (NAS) of at least 4, including at 
least one point for each of steatosis, lobular inflammation, 
and hepatocellular ballooning; and fibrosis stage per the 
NASH Clinical Research Network scoring criteria of F2 
or F3, or F1 with at least one accompanying comorbidity 
(obesity [body-mass index ≥30 kg/m²], type 2 diabetes, or 
Research in context
Evidence before this study
Non-alcoholic steatohepatitis (NASH) is a chronic progressive 
liver disease, which can progress to cirrhosis, hepatic 
decompensation, hepatocellular carcinoma, and liver-related 
death. Currently, there are no approved therapeutic options for 
NASH and treatment is largely limited to lifestyle modifications. 
We searched PubMed for clinical trials treating NASH published 
up to Sept 30, 2019, using the terms “nonalcoholic fatty liver 
disease”, “nonalcoholic steatohepatitis”, “NAFLD”, and “NASH”. 
Early clinical study results for several compounds with various 
mechanisms of action have shown evidence of improvement in 
steatohepatitis or fibrosis, but several such studies lacked 
placebo controls and none of these results have been confirmed 
in a pivotal phase 3 study setting. The farnesoid X receptor is a 
nuclear receptor expressed at high levels in the liver. In animal 
models of liver disease, activation of farnesoid X receptor has 
been associated with both anti-inflammatory and antifibrotic 
effects. The placebo-controlled phase 2b FLINT study showed 
that obeticholic acid, a potent selective farnesoid X receptor 
agonist, improved key histological features of NASH, including 
fibrosis. These promising results led to this randomised, 
placebo-controlled global phase 3 study of obeticholic acid in 
patients with fibrosis due to NASH (REGENERATE).
Added value of this study
To our knowledge, REGENERATE is the first positive phase 3 
study in patients with NASH. In this interim analysis, 
a significantly higher proportion of patients treated with 
obeticholic acid 25 mg had an improvement of fibrosis by at 
least one stage with no worsening of NASH. Additionally, 
a post-hoc analysis showed that obeticholic acid treatment 
resulted in NASH resolution with no worsening of fibrosis based 
on pathologist diagnostic assessment. Obeticholic acid 
treatment also improved underlying disease activity, as shown 
by decreased lobular inflammation and hepatocellular 
ballooning. In addition to improvement in these key histological 
features, meaningful reduction in laboratory parameters, 
including robust normalisation of alanine aminotransferase and 
aspartate aminotransferase, was observed with obeticholic acid 
treatment. Consistent with previous obeticholic acid clinical 
studies, pruritus and increased LDL cholesterol were the most 
commonly reported adverse events. Pruritus incidence was 
generally mild to moderate in severity and dose dependent. 
Greater treatment discontinuation was seen in the obeticholic 
acid 25 mg group, mainly due to protocol requirements. 
Early increases in LDL cholesterol were observed with obeticholic 
acid treatment; however, levels approached baseline by 
month 18.
Implications of all the available evidence
Halting progression to cirrhosis, and therefore preventing 
serious liver-related outcomes, is a key treatment goal in 
patients with NASH with fibrosis. Advanced liver fibrosis is 
strongly associated with risk of liver-related adverse outcomes 
and all-cause mortality, so therapies with proven antifibrotic 
benefit are highly desirable. Because NASH disease progression 
occurs over a number of years, assessing clinical outcomes 
requires long-term evaluation. The positive results of the 
prespecified REGENERATE month-18 interim analysis are based 
on surrogate endpoints considered to be reasonably likely to 
predict clinical benefit, and the study is ongoing through clinical 
outcomes to confirm long-term benefit.
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alanine amino transferase [ALT] >1·5 × upper limit of 
normal [ULN]). Patients were excluded if cirrhosis, other 
chronic liver disease, elevated alcohol consumption 
(>2 units/day for women or >4 units/day for men for 
more than 3 consecutive months in the year before 
screening), or confounding conditions were present; 
ALT greater than or equal to 10 × ULN; or if they had 
HbA1c greater than 9·5% or total bilirubin greater than 
1·5 mg/dL.
A planned interim analysis was done after a minimum 
of 750 randomised patients with fibrosis stages F2 or F3 
reached their actual or planned month-18 visit.
Patients were recruited primarily from hepatologists, 
and from gastroenterologists, academic centres, and 
community sites. All patients provided written informed 
consent. This study is being conducted in accordance 
with the European Union Clinical Trials Directive 
(2001/20/EC and subsequent amendments), 21 Code of 
Federal Regulations Part 312, Good Clinical Practice 
(CPMP/International Council on Harmonisation/135/95), 
and with the ethical principles laid down in the 
Declaration of Helsinki and applicable regulatory 
requirements. The detailed study design, including 
inclusion and exclusion criteria, has been previously 
reported11 and a summary of protocol changes can be 
reviewed on ClinicalTrials.gov.
Randomisation and blinding
Eligible patients were randomly assigned in a 1:1:1 ratio 
to receive daily placebo, obeticholic acid 10 mg, or 
obeticholic acid 25 mg orally. Randomisation was based 
on a predefined randomisation code generated by 
electronic data capture and done using an interactive 
web response system; for patients with fibrosis stage F2 
or F3, randomisation was stratified by both the presence 
of type 2 diabetes and the use of thiazolidinediones or 
vitamin E at baseline. Placebo and obeticholic acid were 
supplied as identical tablets in coded containers. All 
patients, study investigators, and other site research staff 
were blinded to treatment assignment.
Procedures
Patients received daily placebo, obeticholic acid 10 mg, 
or obeticholic acid 25 mg orally, in the form of one tablet. 
Biopsies were obtained at baseline screening and 
month 18 or end of treatment. Histological assessments 
followed standardised criteria to ensure consistency, 
and all biopsies were read centrally. The month-18 
(or early termination) biopsy slides were paired with the 
screening biopsy slides and randomly assigned for 
reading by one of two central expert liver pathologists 
(PB and ZG), who was masked to both the slide sequence 
and the patient’s treatment. Assessments of liver bio-
chemistry including ALT, aspartate aminotransferase 
(AST), γ-glutamyl transferase (GGT), and alkaline 
phosphatase (ALP) were done at each study visit, which 
took place every 3 months for the first 18 months. 
Additionally, glucose, glycated haemoglobin A1c, lipids, 
and bodyweight were measured every 3 months.
Outcomes
This study was designed to assess liver histology at 
month 18 as a surrogate endpoint for clinical outcomes.11 
The primary endpoints were defined as improvement 
in fibrosis (reduction of at least one stage) with no 
worsening of NASH (defined as no increase of hepato-
cellular ballooning, lobular inflammation, or steatosis), 
or NASH resolution (defined as the overall histo patho-
logic interpretation of no fatty liver disease or fatty liver 
disease without steatohepatitis and an NAS of 0 for 
ballooning and 0–1 for inflammation) with no worsening 
of fibrosis. The key secondary endpoint was improvement 
of fibrosis by at least one stage or resolution of NASH, or 
both, without worsening of either. Secondary endpoints 
comprised histological improvement of features of 
NASH as well as NAS, and liver biochemistry.11 A post-
hoc analysis evaluated NASH resolution on the basis of 
the pathologist diagnostic assessment of presence or 
absence of definite steato hepatitis as determined by the 
overall pattern of injury rather than scoring of individual 
NAS parameters.
The end-of-study analysis will evaluate the effect of 
obeticholic acid on clinical outcomes (including pro-
gression to cirrhosis and all-cause mortality) and the 
long-term safety of obeticholic acid, and will be completed 
once approximately 291 adjudicated clinical outcome 
events occur. Patients are expected to have a minimum 
follow-up time of approximately 4 years.
Safety and tolerability of obeticholic acid were assessed 
by analysis of adverse events, vital signs, electro-
cardiograms (ECGs), and clinical laboratory assessments 
(including lipid profile changes); these were all assessed 
once every 3 months, except for ECGs, which were done 
on day 1 and at the month-18 visit. Adverse events were 
graded for severity using Common Terminology Criteria 
for Adverse Events version 4.03. An independent data 
monitoring committee reviewed, and continues to 
review, safety during the study.
Statistical analysis
For the month-18 interim analysis primary efficacy 
endpoint of improvement in fibrosis with no worsening 
of NASH, a sample size of 250 patients per group with 
an assumed 15% discontinuation rate was anticipated to 
provide 98% power to show a significant treatment 
difference between the obeticholic acid (10 mg and 
25 mg) and placebo groups based on the Cochran-
Mantel-Haenszel test with a two-sided type I error (α) at 
the 0·01 level, assuming an adjusted response rate of 
36·7% in each of the obeticholic acid groups and 17·6% 
in the placebo group. The two-sided type I error allocated 
to testing both histological endpoints at the month-18 
interim analysis is 0·02. Inferential testing was done 
sequentially in the dose level, adjusting for multiplicity 
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5189 participants assessed for eligibility
 
1968 randomly assigned 
 
658 assigned to obeticholic acid 25 mg
(safety population)
 
653 assigned to obeticholic acid 10 mg
(safety population)
 
341 excluded from interim 
analysis
95 with fibrosis stage F1 
who reached month 18 
or end of treatment
246 with fibrosis stage 
F2–F3 had not reached 
their month 18 or 
end-of-treatment visit 
by data cutoff
350 excluded from interim 
analysis
96 with fibrosis stage F1 
who reached month 18 
or end of treatment
254 with fibrosis stage 
F2–F3 had not reached 
their month 18 or 
end-of-treatment visit 
by data cutoff
346 excluded from interim 
analysis
96 with fibrosis stage F1 
who reached month 18 
or end of treatment
250 with fibrosis stage 
F2–F3 had not reached 
their month 18 or 
end-of-treatment visit 
by data cutoff
77 discontinued treatment
 14 withdrew consent
 42 due to adverse events
 2 due to site closure
 1 due to non-compliance
 8 physician decision
 5 lost to follow-up
 5 other reasons
312 included in interim analysis
  
308 included in interim analysis
  
657 assigned to placebo 
(safety population)
 
262 completed month 18 or 
end-of-treatment biopsy
 
263 completed month 18 or 
end-of-treatment biopsy
 
253 completed month 18 or 
end-of-treatment biopsy
 
224 included in per-protocol population
311 included in ITT population
226 included in per-protocol population
312 included in ITT population
218 included in per-protocol population
308 included in ITT population
311 included in interim analysis
  
87 excluded from per-protocol
population
84 either did not complete
≥15 months of 
treatment or were not 
on treatment ≥30 days 
before biopsy
3 major protocol 
deviations 
86 excluded from per-protocol
population
78 either did not complete
≥15 months of 
treatment or were not 
on treatment ≥30 days 
before biopsy
8 major protocol 
deviations 
90 excluded from per-protocol
population
80 either did not complete
≥15 months of 
treatment or were not 
on treatment ≥30 days 
before biopsy
10 major protocol 
deviations 
3221 ineligible
 2037 due to histological reasons
 412 did not give informed consent 
or investigator opinion
 330 lab-related reasons
 74 exclusionary medical history
 28 concomitant medications
 136 out of window
 204 unknown
73 discontinued treatment
 26 withdrew consent
 24 due to adverse events
 1 due to site closure
 3 physician decision
 7 lost to follow-up
 12 other reasons
71 discontinued treatment
 20 withdrew consent
 23 due to adverse events
 7 due to site closure
 1 protocol violation
 1 physician decision
 7 lost to follow-up
 12 other reasons
Figure 1: Patient flow diagram
Figure shows patient inclusion in per-protocol and ITT populations, as well as details on discontinuation of treatment and month 18 or end-of-treatment biopsies. Some patients who discontinued 
treatment had an end-of-treatment biopsy. ITT=intention to treat.
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using a truncated Hochberg procedure, to test the 
two primary endpoints within each dose level, starting 
by comparing the obeticholic acid 25 mg group with 
placebo for the two primary endpoints, then comparing 
the obeticholic acid 10 mg group with placebo in the 
intention-to-treat (ITT) population (appendix pp 2–3). 
All other testing and the associated p values reported 
here are not controlled for type I error and are 
considered nominal and descriptive. Success of the 
study was defined as meeting one of the two primary 
endpoints at the predeter mined significance level. For 
histological endpoints, the comparison between treat-
ment groups was done using the Cochran-Mantel-
Haenszel test stratified by the randomisation strata 
(type 2 diabetes and use of thiazolidinediones or 
vitamin E at baseline [yes vs no]). Continuous endpoints, 
change from baseline, and percentage change from 
baseline over time were analysed using a mixed-effect 
repeated measure model with treatment, baseline, visit, 
visit by treatment interaction, and stratification factors 
included in the model. SEs and 95% CIs were presented 
by treatment group. The statistical analysis plan, pri-
mary endpoints, and requirement for study success 
were agreed with the FDA before database lock. More 
information can be found in the appendix (pp 2–3).
All patients (fibrosis stages F1–F3) who received at least 
one dose of study treatment by the prespecified month-18 
interim analysis cutoff date were included in the safety 
population, which was used for all safety and tolerability 
analyses. The primary analysis population for efficacy 
endpoints was the ITT population, comprised of patients 
with more advanced disease (fibrosis stage F2–F3) who 
received at least one dose of treatment and reached, 
or would have reached, the month-18 visit by the pre-
specified interim analysis cutoff date. Efficacy endpoints 
were also analysed in the per-protocol population, 
defined as the ITT population who completed at least 
15 months of treatment, had a biopsy at month 18 or at 
the end of treatment, were on treatment for at least 
30 days immediately preceding biopsy, and did not have 
any major protocol deviations.
This trial was registered with ClinicalTrials.gov, 
NCT02548351, and EudraCT, 20150-025601-6.
Role of the funding source
The REGENERATE study was designed by VR, AJS, 
and ZMY in collaboration with the funder, Intercept 
Pharmaceuticals, which was involved in data collection, 
analysis, and interpretation. Operational and protocol-
specific aspects were supervised by a steering committee 
comprising AJS, MR, PB, QMA, RL, SH, VR, ZG, and 
ZMY (chair). All authors vouch for the fidelity of the 
study to the protocol, the accuracy and completeness 
of the data, and approved publication of the manuscript. 
The first and corresponding authors had full access to 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between Dec 9, 2015, and Oct 26, 2018, 1968 patients 
were enrolled and randomly assigned to one of the 
three treatment groups (figure 1). The ITT population 
included 931 patients randomised to receive placebo 
(n=311), obeticholic acid 10 mg (n=312), or obeticholic See Online for appendix
Placebo 
(n=311)
Obeticholic acid 
10 mg (n=312)
Obeticholic acid 
25 mg (n=308)
Age, years 55 (12) 55 (11) 55 (11)
Sex
Female 187 (60%) 177 (57%) 175 (57%)
Male 124 (40%) 135 (43%) 133 (43%)
Race*
Asian 10/280 (4%) 17/287 (6%) 20/286 (7%)
White 264/280 (94%) 263/287 (92%) 249/286 (87%)
Other 6/280 (2%) 7/287 (2%) 17/286 (6%)
Ethnicity*
Hispanic 52/282 (18%) 42/286 (15%) 47/282 (17%)
Other 230/282 (82%) 244/286 (85%) 235/282 (83%)
Fibrosis stage
F2 142 (46%) 130 (42%) 139 (45%)
F3 169 (54%) 182 (58%) 169 (55%)
NAS ≥6 215/309 (70%) 211 (68%) 208 (68%)
Type 2 diabetes† 175 (56%) 171 (55%) 171 (56%)
Dyslipidaemia 211 (68%) 217 (70%) 205 (67%)
Hypertension 215 (69%) 215 (69%) 196 (64%)
Lipids
Total cholesterol, mg/dL 184·5 (42·7) 185·2 (53·0) 183·5 (44·7)
HDL cholesterol, mg/dL 45·6 (11·1) 44·9 (12·1) 44·3 (11·0)
LDL cholesterol, mg/dL 114·8 (38·2) 113·8 (38·4) 113·3 (38·8)
Triglycerides, mg/dL 178·7 (154·5) 184·6 (195·0) 181·7 (131·6)
Metabolic factors
Fasting glucose, mg/dL 119·1 (38·3) 120·8 (43·6) 119·5 (40·3)
Bodyweight, kg 95·3 (19·0) 95·2 (19·1) 95·4 (19·5)
HOMA-IR 9·6 (11·8) 9·9 (16·9) 8·3 (10·2)
HbA1c 6·6% (1·2) 6·5% (1·2) 6·5% (1·3)
Laboratory parameters
ALT, U/L 79·6 (56·6) 75·6 (47·0) 80·2 (56·4)
AST, U/L 58·9 (40·5) 56·6 (34·0) 57·0 (34·1)
Platelet count, × 10⁹/L 241·9 (67·0) 238·5 (68·0) 237·2 (69·0)
Total bilirubin, mg/dL 0·64 (0·3) 0·65 (0·3) 0·69 (0·3)
Concomitant medication use
Lipid lowering‡ 175 (56%) 170 (54%) 160 (52%)
Statins 144 (46%) 142 (46%) 127 (41%)
Antidiabetic medication 167 (54%) 171 (55%) 159 (52%)
Thiazolidinediones† 5 (2%) 9 (3%) 4 (1%)
Vitamin E† 42 (14%) 34 (11%) 32 (10%)
Data are n (%) or mean (SD). ITT=intention-to-treat. NAS=non-alcoholic fatty liver disease activity score. 
HOMA-IR=Homeostatic Model Assessment of Insulin Resistance. ALT=alanine aminotransferase. AST=aspartate 
aminotransferase. PCSK9=proprotein convertase subtilisin-kexin type 9. *Percentages are calculated on patients for 
whom race or ethnicity information was available. †Randomisation was stratified by presence of type 2 diabetes and 
treatment with thiazolidinediones or vitamin E. ‡Lipid-lowering drugs included statins, fibrates, cholesterol-absorbing 
resins, PCSK9 inhibitors, and omega-3 fatty acids.
Table 1: Demographic and baseline clinical characteristics in the ITT population
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acid 25 mg (n=308). At the time of the interim analysis, 
73 (23%) patients in the placebo group, 71 (23%) in the 
obeticholic acid 10 mg group, and 77 (25%) in the 
obeticholic acid 25 mg group had discontinued treat-
ment (figure 1); 252 (81%) patients receiving placebo, 
253 (81%) receiving obeticholic acid 10 mg, and 
243 (79%) receiving obeticholic acid 25 mg completed 
the month 18 biopsy. An additional 3% of patients in 
each treatment group (ten patients in each group) 
completed any post-baseline biopsy (ie, patients who 
discontinued treatment before month 18 and underwent 
an end-of-treatment biopsy). The per-protocol popu-
lation included 668 patients and the safety population 
included 1968 patients.
In the ITT population, baseline characteristics seemed 
balanced across treatment groups and reflective of a 
non-cirrhotic NASH population (table 1). A majority of 
patients had stage F3 fibrosis (54–58%) and NAS of at 
least 6 (68–70%), indicative of advanced fibrosis and high 
disease activity. Consistent with NASH epidemiology, 
more than half of patients had type 2 diabetes (55–56%), 
and 52–55% overall were receiving antidiabetic medi-
cation at baseline. Additionally, 41–46% of patients were 
receiving statin therapy and a minority were receiving 
NASH-modifying agents, thia zolidinediones (1–3%) and 
vitamin E (10–14%). A similar pattern of baseline 
characteristics was observed in the per-protocol popu-
lation (appendix p 6).
The primary endpoint of fibrosis improvement by at 
least one stage with no worsening of NASH was met by 
37 (12%) patients in the placebo group, 55 (18%) patients 
in the obeticholic acid 10 mg group (p=0·045 vs placebo), 
and 71 (23%) patients in the obeticholic acid 25 mg group 
(p=0·0002 vs placebo) with an obeticholic acid-to-placebo 
response ratio of 1·5 (95% CI 1·0–2·2) for the obeticholic 
10 mg group and 1·9 (1·4–2·8) for the obeticholic 
acid 25 mg group (figure 2; table 2). Obeticholic acid 
25 mg was significant per the prespecified inferential 
testing method. Similar results were observed in the per-
protocol population (figure 2; table 2). Across subgroups 
of interest in the ITT population, an improvement of at 
least one stage in fibrosis with no worsening of NASH 
was observed in the obeticholic acid 25 mg group 
(appendix p 7). Several of the subgroup analyses (ie, use 
of thiazolidinediones or vitamin E, race, and age) were 
limited by imbalances in sample sizes within a given 
subgroup to an extent that precluded meaningful com-
parison (appendix p 7).
In the per-protocol population, which includes patients 
with at least 15 months of treatment, three times as 
many patients achieved an improvement in fibrosis of at 
least one stage compared with progression of fibrosis in 
the obeticholic acid 25 mg group (81 [38%] vs 23 [13%]); 
in the placebo group, a similar number of patients 
improved (51 [23%]) or worsened (46 [21%]; figure 3). 
This analysis suggests that on a placebo-adjusted basis, 
after 18 months of treatment, four to five patients with 
NASH and fibrosis stage F2–F3 would need to be treated 
with obeticholic acid 25 mg for one such patient to 
achieve either improvement (≥1 stage) or no worsening 
of fibrosis.
The primary endpoint of NASH resolution (based on 
no hepatocellular ballooning and no residual lobular 
inflammation) with no worsening of fibrosis did not 
meet statistical significance in the ITT population 
(25 [8%] patients in the placebo group vs 35 [11%] in the 
obeticholic acid 10 mg group [p=0·18] or 36 [12%] in the 
obeticholic acid 25 mg group [p=0·13]), with a response 
ratio of 1·4 (95% CI 0·9–2·3) for obeticholic acid 10 mg 
and 1·5 (0·9–2·4) for obeticholic acid 25 mg (figure 2; 
table 2). Similar results were observed in the per-protocol 
population (figure 2; table 2). Despite not meeting the 
NASH resolution endpoint, a dose-dependent response 
was observed in the ITT population, with more patients 
in the obeticholic acid 25 mg group showing at least a 
1-point improvement in scores in key histological 
features of NASH compared with the placebo group 
(136 [44%] patients vs 111 [36%] for lobular inflammation 
[p=0·032] and 108 [35%] vs 72 [23%] for hepatocellular 
ballooning [p=0·0011]; table 2; appendix p 8).
In a post-hoc analysis, NASH resolution was evaluated 
by assessing a change from presence of definite steato-
hepatitis at baseline to absence of definite steatohepatitis 
Figure 2: Primary endpoints in the ITT population
The proportion of patients with improvement in fibrosis of at least one stage and no worsening of NASH and the 
proportion of patients with resolution of NASH and no worsening of fibrosis are shown in the ITT and per-protocol 
populations. Fibrosis improvement was evaluated per NASH Clinical Research Network criteria; no worsening of 
NASH defined as no worsening of hepatocellular ballooning, lobular inflammation, or steatosis. NASH resolution 
defined as overall pathologist assessment of no steatohepatitis, and hepatocellular ballooning=0 and lobular 
inflammation=0 or 1. ITT=intention to treat. NASH=non-alcoholic steatohepatitis. *Significant in accordance with 
the statistical analysis plan as agreed with the US Food and Drug Administration.
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(without worsening of fibrosis) at month 18. This 
pathologist diagnostic assessment of NASH, based on 
the overall pattern of liver injury, showed that in the ITT 
population approximately twice as many patients in the 
obeticholic acid 25 mg group achieved NASH resolution 
compared with the placebo group (71 [23%] vs 38 [12%], 
p=0·0004; appendix p 9). A similar dose-dependent 
response was observed in the per-protocol population 
(63 [29%] vs 35 [16%], p=0·0005; appendix p 9).
The key secondary endpoint of improvement of fibrosis 
of at least one stage or resolution of NASH, without 
worsening of either, was observed in 49 (16%) patients in 
the placebo group, 67 (21%) in the obeticholic acid 10 mg 
group, and 84 (27%) in the obeticholic acid 25 mg patients 
in the ITT population (table 2; appendix p 10). A signifi-
cantly higher proportion of patients receiving obeticholic 
acid 25 mg compared with placebo showed improvement 
in NAS by at least two points with no worsening of 
fibrosis, had no disease progression as assessed by no 
worsening of fibrosis and no worsening of NASH, and 
had improvement in fibrosis of at least two stages 
(table 2). Additional secondary NASH and fibrosis 
endpoints are provided in table 2.
Favourable changes in key liver enzymes were observed 
in patients treated with obeticholic acid. Early dose-
dependent decreases in ALT and AST were observed by 
month 3 and continued through month 18 (mean change 
from baseline at month 18 in ALT: –15·6 U/L [SE 3·3] for 
the placebo group, –23·8 U/L [2·6] for the obeticholic 
acid 10 mg group, and –36·0 U/L [3·6] for the obeticholic 
acid 25 mg group; mean change in AST of –9·8 U/L [2·4] 
for the placebo group, –14·1 U/L [2·1] for the obeticholic 
acid 10 mg group, and –20·4 U/L [2·3] for the obeticholic 
acid 25 mg group; figure 4). These changes correspond to 
a decrease in ALT of 6% for placebo, 26% for obeticholic 
acid 10 mg, and 33% for obeticholic acid 25 mg and in 
AST of 4%, 19%, and 24% (figure 4). A post-hoc analysis 
showed that a higher proportion of patients receiving 
obeticholic acid with elevated ALT and AST at baseline 
achieved levels below the ULN at month 18 compared 
ITT population (N=931) Per-protocol population (N=668)
Placebo 
(n=311)
Obeticholic acid 10 mg 
(n=312)
Obeticholic acid 25 mg 
(n=308)
Placebo 
(n=224)
Obeticholic acid 10 mg 
(n=226)
Obeticholic acid 25 mg 
(n=218)
Patients RR (95% CI); 
p value
Patients RR (95% CI); 
p value
Patients RR (95% CI); 
p value
Patients RR (95% CI); 
p value
Primary endpoints
Improvement of fibrosis with no 
worsening of NASH
37 (12%) 55 (18%) 1·5 (1·0–2·2); 
p=0·045
71 (23%) 1·9 (1·4–2·8); 
p=0·0002
29 (13%) 47 (21%) 1·6 (1·1–2·5); 
p=0·025
60 (28%) 2·2 (1·4–3·2); 
p<0·0001
Resolution of NASH with no worsening 
of fibrosis
25 (8%) 35 (11%) 1·4 (0·9–2·3); 
p=0·18
36 (12%) 1·5 (0·9–2·4); 
p=0·13
23 (10%) 34 (15%) 1·5 (0·9–2·4); 
p=0·11
31 (14%) 1·4 (0·9–2·3); 
p=0·18
Secondary endpoints*
Improvement of fibrosis by ≥1 stage or 
resolution of NASH without worsening 
of either
49 (16%) 67 (21%) 1·4 (1·0–1·9); 
p=0·068
84 (27%) 1·7 (1·3–2·4); 
p=0·0005
41 (18%) 59 (26%) 1·4 (1·0–2·1); 
p=0·041
71 (33%) 1·8 (1·3–2·5); 
p=0·0004
No worsening of fibrosis and no 
worsening of NASH
117 (38%) 127 (41%) 1·1 (0·9–1·3); 
p=0·43
147 (48%) 1·3 (1·1–1·5); 
p=0·011
100 (45%) 109 (48%) 1·1 (0·9–1·3); 
p=0·43
125 (57%) 1·3 (1·1–1·6); 
p=0·0062
Improvement of NAS by ≥2 with no 
worsening of fibrosis
76 (24%) 94 (30%) 1·2 (1·0–1·6); 
p=0·11
112 (36%) 1·5 (1·2–1·9); 
p=0·0012
69 (31%) 82 (36%) 1·2 (0·9–1·5); 
p=0·19
96 (44%) 1·4 (1·1–1·8); 
p=0·0035
Improvement of fibrosis and resolution 
of NASH as a composite endpoint†
13 (4%) 23 (7%) 1·8 (0·9–3·4); 
p=0·090
23 (7%) 1·8 (0·9–3·4); 
p=0·080
11 (5%) 22 (10%) 2·0 (1·0–4·1); 
p=0·045
20 (9%) 1·9 (1·0–3·9); 
p=0·064
Improvement in fibrosis by ≥2 stages 15 (5%) 19 (6%) 1·3 (0·7–2·4); 
p=0·49
30 (10%) 2·0 (1·1–3·7); 
p=0·018
10 (4%) 16 (7%) 1·6 (0·8–3·5); 
p=0·22
29 (13%) 3·1 (1·5–6·1); 
p=0·0008
Resolution of fibrosis 4 (1%) 8 (3%) 2·0 (0·6–6·4); 
p=0·25
10 (3%) 2·5 (0·8–7·9); 
p=0·10
4 (2%) 8 (4%) 2·1 (0·6–6·7); 
p=0·21
9 (4%) 2·4 (0·7–7·6); 
p=0·14
≥1-point improvement in steatosis 118 (38%) 127 (41%) 1·1 (0·9–1·3); 
p=0·49
127 (41%) 1·1 (0·9–1·3); 
p=0·40
97 (43%) 108 (48%) 1·1 (0·9–1·4); 
p=0·33
113 (52%) 1·2 (1·0–1·5); 
p=0·072
≥1-point improvement in lobular 
inflammation
111 (36%) 123 (39%) 1·1 (0·9–1·4); 
p=0·34
136 (44%) 1·2 (1·0–1·5); 
p=0·032
94 (42%) 104 (46%) 1·1 (0·9–1·4); 
p=0·38
114 (52%) 1·3 (1·0–1·5); 
p=0·031
≥1-point improvement in hepatocellular 
ballooning
72 (23%) 85 (27%) 1·2 (0·9–1·5); 
p=0·24
108 (35%) 1·5 (1·2–2·0); 
p=0·0011
64 (29%) 77 (34%) 1·2 (0·9–1·6); 
p=0·19
95 (44%) 1·5 (1·2–2·0); 
p=0·0008
Pathologist assessment of NASH 
resolution with no worsening of fibrosis‡
38 (12%) 51 (16%) 1·3 (0·9–2·0); 
p=0·14
71 (23%) 1·9 (1·3–2·7); 
p=0·0004
35 (16%) 48 (21%) 1·4 (0·9–2·0); 
p=0·11
63 (29%) 1·9 (1·3–2·7); 
p=0·0005
ITT=intention-to-treat. RR=response ratio. NASH=non-alcoholic steatohepatitis. NAS=non-alcoholic fatty liver disease activity score. *p values compare obeticholic acid treatment with placebo, using the 
Cochran-Mantel-Haenszel test, stratified by baseline diabetes status (yes vs no) and use of thiazolidinediones or vitamin E at baseline (yes vs no). †Improvement of fibrosis and resolution of NASH is defined as a 
composite endpoint where both of the primary endpoints are met in the same patient. ‡Post-hoc analysis of NASH resolution as defined by the pathologist’s overall assessment of a change from presence of 
definite steatohepatitis at baseline to absence of definite steatohepatitis (without worsening of fibrosis) at month 18.
Table 2: Efficacy endpoints
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with placebo (appendix p 11). GGT levels declined 
rapidly and were generally stable after month 3 (change 
at month 18: 1% increase for the placebo group, 
24% decrease for the obeticholic acid 10 mg group, and 
38% decrease for the obeticholic acid 25 mg group; 
figure 4). Increases in ALP were observed with obeticholic 
acid treatment, but levels remained below the ULN 
throughout the study period (change at month 18: 
1% decrease for the placebo group, 9% increase for 
the obeticholic acid 10 mg group, and 20% increase for 
the obeticholic acid 25 mg group; figure 4).
Additionally, treatment with obeticholic acid resulted 
in a dose-dependent decrease in bodyweight at month 18 
(mean change from baseline –0·7 kg [SE 0·4] for the 
placebo group, –1·8 kg [0·4] for the obeticholic acid 
10 mg group, and –2·2 kg [0·3] for the obeticholic acid 
25 mg group).
1968 patients were included in the safety population, 
comprised of fibrosis stage F1 (290 [15%] patients), 
stage F2 (698 [35%]), and stage F3 (980 [50%]; figure 1). 
The duration of exposure was generally similar across 
treatment groups. Overall, treatment-emergent adverse 
events occurred in 548 (83%) patients in the placebo 
group, 579 (89%) in the obeticholic acid 10 mg group, 
and 601 (91%) in the obeticholic acid 25 mg group 
(table 3). Most treatment-related adverse events were of 
mild or moderate severity (table 3). The frequency of 
serious adverse events was similar across treatment 
groups (11–14%) and no single serious adverse event 
occurred in more than 1% of patients in any treatment 
group (table 3). The most frequent adverse event was 
pruritus (table 3). The incidence of pruritus was highest 
during the first 3 months of treatment with obeticholic 
acid, and generally mild to moderate in severity. 
Treatment discontinuation due to pruritus occurred in 
five (<1%) patients in the placebo group, five (<1%) in 
the obeticholic acid 10 mg group, and 57 (9%) in the 
obeticholic acid 25 mg group. Of the 57 patients in the 
obeticholic acid 25 mg group who discontinued due to 
pruritus, 36 discontinuations were protocol mandated 
based on the investigator-assessed grade of the event.
In patients receiving obeticholic acid, LDL cholesterol 
increased by month 1 (mean change from baseline 
–3·0 mg/dL [SE 0·9] in the placebo group, 17·8 mg/dL 
[1·0] in the obeticholic acid 10 mg group, and 
23·8 mg/dL [1·1] in the obeticholic acid 25 mg group) 
and decreased thereafter, approaching baseline by 
month 18 (mean change from baseline –7·1 mg/dL [1·7] 
for the placebo group, 1·4 mg/dL [2·0] for the obeticholic 
acid 10 mg group, and 2·7 mg/dL [2·1] for the obeticholic 
acid 25 mg group; appendix p 12). 380 patients started 
statin therapy during the study (66 in the placebo group, 
155 in the obeticholic acid 10 mg group, and 159 in the 
obeticholic acid 25 mg group). Among obeticholic acid-
treated patients who initiated statins, the initial LDL 
cholesterol increases reversed to below baseline levels as 
of month 6 and were sustained through month 18 
(appendix p 13). There was no clear pattern of fibrosis 
improvement by statin use. Levels of HDL cholesterol 
showed dose-dependent decreases by month 1 (mean 
change from baseline –0·7 mg/dL [0·2] in the placebo 
group, –1·8 mg/dL [0·2] in the obeticholic acid 10 mg 
group, and –4·6 mg/dL [0·3] in the obeticholic acid 
25 mg group) and were sustained through month 18; 
mean HDL cholesterol remained within the normal 
limit (>40 mg/dL) at all timepoints (appendix p 12). 
Changes in total cholesterol over time were similar to 
those for LDL cholesterol (appendix p 12). A dose-
dependent decrease in triglycerides was observed by 
month 1 in the obeticholic acid groups, with levels 
continuing to decline with a maximum mean change 
Figure 3: Regression or progression of fibrosis by at least one stage in the 
per-protocol population
The proportion of patients with improved or worsened fibrosis by at least 
one stage is shown for the 656 patients in the per-protocol population with 
available fibrosis stage data at month 18 or end of treatment.
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Figure 4: Changes in liver biochemistry over time in the ITT population
Mean values of change from baseline up to month 18 are shown for patients from each treatment group in the 
ITT population, with vertical bars indicating SEs. ALP=alkaline phosphatase; ALT=alanine aminotransferase. 
AST=aspartate aminotransferase. GGT=γ-glutamyl transferase. ITT=intention to treat. ULN=upper limit of normal.
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from baseline of –37·4 mg/dL in the obeticholic acid 
25 mg group at month 18 (appendix p 12).
The incidence of cardiovascular adverse events and 
serious adverse events was similar across treatment 
groups (adverse events: 30 [5%] in the placebo group, 
43 [7%] in the obeticholic acid 10 mg group, and 42 [6%] 
in the obeticholic acid 25 mg group; serious adverse 
events: ten [2%] placebo, nine [1%] obeticholic acid 
10 mg, and 13 [2%] obeticholic acid 25 mg). Effects on 
glycaemic parameters were evaluated by baseline dia-
betes status (appendix p 14). In patients with type 2 
diabetes, obeticholic acid treatment was associated with 
an early transient increase in glucose and HbA1C with 
return to levels similar to placebo by month 6. No 
clinically meaningful changes were noted in patients 
without diabetes. Blood pressure was generally stable, 
but variable, with no significant difference between 
treatment groups. Other vital signs were not affected by 
study treatments (data not shown).
Gallstone-related adverse events occurred in two (<1%) 
patients in the placebo group, seven (1%) in the obeticholic 
acid 10 mg group, and 19 (3%) in the obeticholic acid 
25 mg group. Pancreatitis, a more serious and potentially 
gallstone-related event, was rare and evenly distributed 
across treatment groups (one [<1%] patient in each of 
the placebo and obeticholic acid 10 mg groups and 
three [<1%] patients in the obeticholic acid 25 mg group). 
Hepatic serious adverse events were uncommon, and 
each case was reviewed by independent expert hepato-
logists. Although more events occurred in the obeticholic 
acid 25 mg group (six [1%] patients) than the obeticholic 
acid 10 mg group (two [<1%] patients) or placebo group 
(two [<1%] patients), expert reviewers did not identify any 
consistent pattern of liver injury and all cases were 
associated with confounding concomitant medications or 
severe intercurrent illness.
Three deaths occurred on study: two in the placebo 
group (bone cancer and cardiac arrest) and one in the 
obeticholic acid 25 mg group (glioblastoma). None were 
considered related to study treatment.
Discussion
To our knowledge, this study is the first positive phase 3 
trial in NASH and represents a landmark in the develop-
ment of new therapies for an increasingly common 
chronic liver disease.12–15 Treatment with obeticholic acid 
25 mg met the primary endpoint of improvement in 
fibrosis with no worsening of NASH in patients with 
stage F2 or F3 fibrosis, at the month-18 interim analysis. 
The robust antifibrotic effect of obeticholic acid was 
dose dependent and consistent across different patient 
populations and subgroups, and was further supported 
by fibrosis-related secondary endpoints, including an 
improvement in fibrosis of at least two stages. Per the 
draft guidance from the FDA on efficacy endpoints for 
clinical trials in NASH, improvement in fibrosis by at 
least one stage with no worsening of NASH is reasonably 
likely to predict clinical benefit.10 Patients with NASH 
have an almost 65 times greater risk of liver-specific 
mortality and almost three times greater risk of overall 
mortality compared with healthy individuals.14 Fibrosis 
has been shown to be the strongest histological predictor 
of liver-related adverse outcomes, including liver-related 
death.16–19 Treatment with obeticholic acid 25 mg both 
improved fibrosis and prevented progression of fibrotic 
disease. To slow or reverse the progression of fibrosis is 
the ultimate goal of NASH treatment as fibrosis is 
the most reliable predictor of liver-related mortality 
and, once patients progress to cirrhosis, preventing 
complications of cirrhosis can become even more 
difficult.16,18
Placebo 
(n=657)
Obeticholic acid 
10 mg (n=653)
Obeticholic acid 
25 mg (n=658)
Treatment-emergent and serious adverse events
At least one treatment-emergent adverse event 548 (83%) 579 (89%) 601 (91%)
Severity*
Mild 160 (24%) 163 (25%) 130 (20%)
Moderate 294 (45%) 323 (49%) 338 (51%)
Severe 87 (13%) 89 (14%) 130 (20%)
Life-threatening 5 (1%) 4 (1%) 2 (<1%)
Death 2 (<1%) 0 1 (<1%)
Leading to treatment discontinuation 41 (6%) 39 (6%) 83 (13%)
Serious adverse events 75 (11%) 72 (11%) 93 (14%)
Adverse events occurring in ≥5% of patients in either obeticholic acid group
Skin and subcutaneous tissue disorders
Pruritus 123 (19%) 183 (28%) 336 (51%)
Grade 1 (mild or localised) 90 (14%) 113 (17%) 148 (22%)
Grade 2 (intense or wide spread) 30 (5%) 67 (10%) 152 (23%)
Grade 3 (intense or widespread and limit 
activities of daily living)
3 (<1%) 3 (<1%) 36 (5%)
Gastrointestinal disorders
Nausea 77 (12%) 72 (11%) 83 (13%)
Constipation 36 (5%) 65 (10%) 70 (11%)
Abdominal pain 62 (9%) 66 (10%) 67 (10%)
Diarrhoea 79 (12%) 44 (7%) 49 (7%)
Abdominal pain upper 35 (5%) 46 (7%) 45 (7%)
Vomiting 33 (5%) 34 (5%) 44 (7%)
Abdominal distension 23 (4%) 31 (5%) 31 (5%)
Infections and infestations
Urinary tract infection 49 (7%) 54 (8%) 62 (9%)
Upper respiratory tract infection 44 (7%) 47 (7%) 54 (8%)
Nasopharyngitis 41 (6%) 34 (5%) 45 (7%)
Bronchitis 28 (4%) 34 (5%) 35 (5%)
Sinusitis 35 (5%) 36 (6%) 30 (5%)
Investigations
LDL cholesterol increased 47 (7%) 109 (17%) 115 (17%)
Blood cholesterol increased 12 (2%) 30 (5%) 38 (6%)
Musculoskeletal and connective tissue disorders
Arthralgia 55 (8%) 50 (8%) 50 (8%)
Back pain 50 (8%) 56 (9%) 40 (6%)
(Table 3 continues on next page)
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Although the percentage of patients achieving 
NASH resolution was not significant between obeticholic 
acid and placebo, more patients receiving obeticholic 
acid 25 mg showed improvements in hepatocellular 
ballooning and lobular inflammation, the two key 
histological features of the prespecified NASH resolution 
endpoint. These data are relevant given that features of 
steatohepatitis, such as hepatocellular ballooning, are 
predictive of increased liver-related events and reduced 
liver transplant-free survival.19 Additionally, more patients 
receiving obeticholic acid 25 mg had an improvement of 
at least two points in NAS with no worsening of fibrosis, 
the primary endpoint traditionally used in phase 2 studies 
such as FLINT7 and PIVENS,20 indicating that obeticholic 
acid reduces NASH disease activity.
Twice as many obeticholic acid 25 mg patients compared 
with placebo achieved NASH resolution as determined 
by the post-hoc pathologist diagnostic assessment of 
the absence of definite steatohepatitis at month 18. This 
evaluation was based on an assessment of the overall 
pattern of histological lesions or injury, as opposed to the 
more rigid categorical scoring system of the prespecified 
methodology described above. This finding has clinical 
relevance given that this definition is commonly used to 
diagnose NASH in clinical practice, as well as in natural 
history studies evaluating the correlation of definite 
NASH and mortality.16 The assessment of NASH reso-
lution based on NAS parameters appears to be more rigid 
and might be associated with greater intra-rater and inter-
rater variability compared with the diagnostic classification 
of NASH.21 The NAS, a tool designed to measure disease 
activity and severity in NASH, is distinct from a clinical 
diagnosis of definite steatohepatitis. In an investigation 
into the relationship between NAS and the diagnosis of 
steato hepatitis, threshold values of NAS did not always 
correlate with pathologist overall assessment of presence 
of NASH.22 Therefore, as the field continues to evolve, it 
might be more appropriate to establish the presence or 
absence of NASH using histological diagnostic criteria as 
an endpoint, as has been done by the National Institute of 
Diabetes and Digestive and Kidney Diseases’ NASH 
Clinical Research Network in the past.
In addition to consistent improvements in multiple 
histological parameters, improvement in liver health 
was also evident based on clinically meaningful, dose-
dependent improvements in markers of liver injury 
(ALT and AST) and oxidative stress (GGT). The modest 
increases in ALP are consistent with earlier observations 
and are associated with an on-target effect of farnesoid 
X receptor activation.
Lifestyle modifications including weight loss have been 
shown to be an effective non-pharmacological therapy 
for NAFLD. Weight loss greater than 7% has been 
associated with improvement in NAS and weight loss of 
at least 10% with improvement in fibrosis.23 Obeticholic 
acid-treated patients experienced weight loss of appro-
ximately 2%, an amount lower than that expected to have 
an effect on histological parameters of NASH. Although 
modest, the effect of obeticholic acid on weight is 
important to note given the prevalence of obesity and 
metabolic abnormalities in this population.
Based on a substantial safety population including 
almost 2000 patients, of whom approximately 900 were 
exposed for at least 18 months, obeticholic acid was 
generally well tolerated. Most adverse events were mild 
to moderate in severity and were generally consistent 
with the known safety profile of obeticholic acid.7 As 
previously seen, mild-to-moderate pruritus was the most 
commonly reported adverse event, with a dose-dependent 
incidence. More patients in the obeticholic acid 25 mg 
group experienced pruritus that led to treatment 
discontinuation; however, most randomised patients 
were ongoing in the study through at least month 18 and 
the overall treatment discontinuation rate was similar 
to placebo. The impact of pruritus in this study on 
patient-reported outcomes and its relationship to 
obeticholic acid is being investigated.24 The incidence of 
hepatic adverse events was balanced across treatment 
groups, and serious hepatic events were rare; although 
numerically more occurred in the obeticholic acid 
25 mg treated group, there was no clear pathological 
pattern seen consistently among these serious adverse 
events and all cases were confounded by concomitant 
medications or severe intercurrent illness. Treatment 
with obeticholic acid was associated with serum lipid 
changes that were consistent with a class effect of 
farnesoid X receptor activation, as well as small and 
generally transient increases in glycaemic parameters. 
Such increases were manageable by clinical practice 
measures. The effect of lipid changes on cardiovascular 
risk should be assessed in the context of other obeticholic 
Placebo 
(n=657)
Obeticholic acid 
10 mg (n=653)
Obeticholic acid 
25 mg (n=658)
(Continued from previous page)
Metabolism and nutrition disorders
Hyperlipidaemia 18 (3%) 42 (6%) 55 (8%)
Diabetes 36 (5%) 46 (7%) 45 (7%)
Hypercholesterolaemia 14 (2%) 35 (5%) 29 (4%)
General disorders and administration site conditions
Fatigue 88 (13%) 78 (12%) 71 (11%)
Nervous system disorders
Headache 51 (8%) 42 (6%) 34 (5%)
Dizziness 28 (4%) 32 (5%) 25 (4%)
Respiratory, thoracic, and mediastinal disorders
Cough 27 (4%) 29 (4%) 38 (6%)
Vascular disorders
Hypertension 28 (4%) 36 (6%) 39 (6%)
Table is arranged by descending order of incidence (system organ class and preferred term within system organ class) 
in the obeticholic acid 25 mg group, followed by descending order of incidence in the obeticholic acid 10 mg group. 
*Patients reporting more than one adverse event are counted only once using the highest severity.
Table 3: Summary of treatment-emergent adverse events in the safety population
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acid-related reductions in risk factors, including a 
decrease in bodyweight, serum triglyceride levels, and 
GGT, a promising marker for assessing cardiovascular 
risk, as well as improvements in liver fibrosis, which 
might have a downstream effect on cardiovascular 
risk.19,25–27 The incidence of cardiovascular adverse events 
and serious adverse events was low and similar across 
treatment groups and continues to be monitored in the 
outcomes portion of the study.
The results of the interim analysis reported here are 
clinically relevant in the context of fibrosis due to NASH 
but might underestimate the long-term benefit of 
obeticholic acid on the target illness. Improvement in 
fibrosis, a generally slow process, was observed at the 
month-18 interim analysis of the ongoing study, and the 
effect size might increase with prolonged therapy. This 
has been shown with other interventions that reported 
improvement in fibrosis at early timepoints with a 
greater effect over the longer term. For example, tenofovir 
treatment resulted in 10% fewer patients with hepatitis B 
virus-associated advanced fibrosis or cirrhosis after the 
first year of treatment (28% vs 38% at baseline).28 In 
the tenofovir study, patients continued to improve on 
treatment, and the proportion of patients with advanced 
fibrosis or cirrhosis declined to 12% at year 5.27 In 
REGENERATE, the continuing improvement in liver 
enzyme markers of fibrosis such as ALT and AST suggest 
the potential for further increase in antifibrotic response. 
Data from the ongoing long-term outcomes portion of 
the study will inform whether prolonged therapy will 
result in a greater antifibrotic benefit.
This is a prespecified interim analysis of an ongoing 
study and the histological outcomes, in particular fibrosis 
stage, have been shown to be reasonably likely to predict 
clinical outcomes and therefore supports regulatory 
submission based upon the conditional approval path-
way. However, a limitation of this analysis is that clinical 
outcomes data are not yet available. Additionally, the 
study population consists of patients selected on the basis 
of biopsy evidence of NASH and fibrosis; however, 
physicians increasingly rely on non-invasive means to 
diagnose and stage patients with NASH with fibrosis, 
which might have an implication for the real world 
relevance of the results. Non-invasive assessments of 
liver fibrosis such as the Fibrosis-4 Index and transient 
elastography are potentially more sensitive continuous 
parameters than categorical assessment of change in 
histological fibrosis stage; these were assessed throughout 
the study and will be reported at a later date. Finally, this 
interim analysis was completed with evolving regulatory 
authority guidances in which, for example, the definition 
of histological NASH resolution has changed, with the 
implication that future pivotal study designs could 
continue to be modified.
In conclusion, the totality of data from the month-18 
interim analysis of this phase 3 study provides strong 
evidence that obeticholic acid treatment improves 
clinically significant histological endpoints deemed 
reasonably likely to predict clinical benefit, and affirms 
the positive benefit–risk ratio of obeticholic acid for the 
treatment of NASH with fibrosis. Beneficial effects of 
obeticholic acid on fibrosis and key components of 
NASH disease activity were robust, based on the observed 
consistency of results across multiple histological 
endpoints with reproducible response ratios, as well as 
the evident dose-response and markedly consistent 
benefit across analysis populations. Treatment with 
obeticholic acid had a beneficial effect on other markers 
of hepatocellular injury (ALT and AST) and oxidative 
stress (GGT). Obeticholic acid was generally well 
tolerated, with a profile that is generally consistent with 
prior studies. Following the month-18 interim analysis, 
this study continues in a blinded fashion, and patients 
will be followed up over an extended period through 
clinical outcomes (including all-cause mortality and 
liver-related clinical outcomes) and long-term safety, to 
confirm clinical benefit. In a chronic liver disease with 
no approved therapies and potential for serious sequelae, 
these findings provide compelling evidence that patients 
with non-cirrhotic advanced fibrosis due to NASH might 
benefit from obeticholic acid treatment.
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